Ernexa Therapeutics, Inc. (ERNA)
4.30
+0.14
(+3.24%)
USD |
NASDAQ |
Sep 14, 10:51
Ernexa Therapeutics Net Income (Quarterly) : -4.009M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.009M |
| March 31, 2026 | -5.506M |
| December 31, 2025 | -1.502M |
| September 30, 2025 | -1.24M |
| June 30, 2025 | -3.139M |
| March 31, 2025 | -8.202M |
| December 31, 2024 | -5.759M |
| September 30, 2024 | -26.60M |
| June 30, 2024 | -5.529M |
| March 31, 2024 | -6.647M |
| December 31, 2023 | -6.153M |
| September 30, 2023 | -5.591M |
| June 30, 2023 | -4.508M |
| March 31, 2023 | -5.416M |
| December 31, 2022 | -4.489M |
| September 30, 2022 | -7.316M |
| June 30, 2022 | -3.398M |
| March 31, 2022 | -9.375M |
| December 31, 2021 | -7.952M |
| September 30, 2021 | -85.99M |
| June 30, 2021 | -10.08M |
| March 31, 2021 | -18.52M |
| December 31, 2020 | -21.46M |
| September 30, 2020 | -2.020M |
| June 30, 2020 | -2.033M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.019M |
| December 31, 2019 | -1.293M |
| September 30, 2019 | -0.351M |
| June 30, 2019 | -0.09M |
| March 31, 2019 | -0.313M |
| December 31, 2018 | 0.052M |
| September 30, 2018 | 0.222M |
| June 30, 2018 | -0.124M |
| March 31, 2018 | -0.409M |
| December 31, 2017 | -0.639M |
| September 30, 2017 | -0.184M |
| June 30, 2017 | -0.164M |
| March 31, 2017 | -0.09M |
| December 31, 2016 | -0.459M |
| September 30, 2016 | -0.573M |
| June 30, 2016 | -0.85M |
| March 31, 2016 | -1.041M |
| December 31, 2015 | -0.99M |
| September 30, 2015 | -1.348M |
| June 30, 2015 | -2.625M |
| March 31, 2015 | -2.263M |
| December 31, 2014 | -1.718M |
| September 30, 2014 | -1.315M |
| June 30, 2014 | -1.348M |
| March 31, 2014 | -0.649M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cerenome, Inc. | -9.006M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.009M |
| EPS Diluted (Quarterly) | -3.396 |
| Enterprise Value | 0.1951M |
| Earnings Yield | -440.1% |
| Normalized Earnings Yield | -436.53 |